ClinicalTrials.gg
RecruitingNCT04916132PRIMETIME2Updated Dec 24, 2025

Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

An observational study in Chronic Kidney Diseases, Albuminuria and Diabetic Kidney Disease, sponsored by Herlev Hospital. Recruiting at 13 sites in Denmark. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Herlev Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Renal Insufficiency, Chronic with a site in Denmark — 27 open to participants now, 35 under way, 9 of them phase 3. Renal Insufficiency, Chronic · Denmark.

Planned enrollment
14th of 26
300 · median 321
Started
2021
with 11 others
Observational
26 of 116
9 open now
Primary completion
2043-12
later than 33 of 34 live
Registered
73rd of 116
by date
Lead sponsor
6 of 116
Herlev Hospital

Among the 116 studies in Renal Insufficiency, Chronic with a site in Denmark, this one is the 14th largest by planned enrollment of the 26 observational ones that give a count, is one of 12 that started in 2021, is one of 26 observational ones, reaches primary completion later than 33 of the 34 other live ones, and was the 73rd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

27 of the 116 studies in Renal Insufficiency, Chronic with a site in Denmark are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Renal Insufficiency, Chronic with a site in Denmark, or all of them as a file.
02

Study summary

a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.

Read the detailed description

The PRIMETIME project is made to bring together molecular, translational and clinical scientists to create collaborations and build a scientific bridge between diabetology, nephrology, clinical biochemistry, and pathology. The ultimately goal is to bring forward an improved understanding of the most frequent cause of end stage renal disease: DKD. We aim to improve the diagnostic accuracy as well as the treatment precision by investigating in detail the features of histology and protein expression in both retrospective(WP1) and prospective(WP2) kidney biopsy material.

PRIMETIME WP2 is a prospective, observational, multi-center study with a cohort of 300 patients. We plan to create a systematically unselected cohort of patients with Type2 diabetes and macroalbuminuria as a sign of kidney injury. Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome. The participants will afterward be followed in 20 years.Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.

03

Conditions studied

  • Chronic Kidney Diseases
  • Albuminuria
  • Diabetic Kidney Disease
  • Diabetic Nephropathies
  • Diabetes type2
  • Molecular Sequence Variation
  • Kidney Biopsy

Keywords

  • diabetic nephropaty
  • precision medicine
  • kidney biopsy
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

People with type 2 diabetes, albuminuria and eGFR > 30 who are willing to undergo a kidney biopsy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Written
  • Diagnosis with T2DM according to the American diabetes Association (20)
  • >30 mL/min/1.73 m2 (maximum six months old)
  • urine-albumin/creatinine-ratio (uACR) > 700 mg/g or 24 hours urine albumin >700 mg on more than one measurement

Exclusion criteria

Exclusion Criteria:

  • Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney or the last 6 months before kidney biopsy
  • Factors that increases the risk of complications due to kidney biopsy:

    • \< 6 mmol/L
    • >1,4 at the time for biopsy
    • count \< 100 x 109/l
    • Uncontrolled high blood pressure (defined as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg)
    • Only one functioning kidney
    • Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy
    • Multiple bilateral kidney cysts
    • Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy
    • Unwilling to receive blood transfusion
    • Unable to lie flat in bed six hours after biopsy
    • Any other for percutaneous kidney biopsy according to local clinical guidelines
  • Unable to understand written and oral information
  • Kidney transplant recipient
  • Previous medical kidney biopsy
  • Women who are pregnant or planning to become pregnant before the kidney biopsy is performed
  • Treatment with Marcoumar (all other anticoagulants are accepted)
  • High thromboembolic risk combined with held in anticoagulation therapy according to the report "Perioperative regulation of antithrombotic treatment" (PRAB) (22)

    • mechanical heart valve
    • atrial fibrillation AND CHA2DS2-VASc> 5 and/or stroke within the last three months
    • recurrent venous thromboembolism OR venous thromboembolism within the last three months
    • less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))
    • less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))
    • less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)
    • less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)
    • less than 3 months after revascularization in individuals with stable CAD (PCI with DES)
    • less than 3 months after stroke, or (TIA)
  • Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy

If a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Peolpe with T2DM and albuminuria

    Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.

    Procedure: Kidney Biopsy

Interventions

  • ProcedureKidney Biopsy

    Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis

06

What researchers measure

Primary outcomes

  1. Prevalence

    To investigate the prevalence of biopsy-proven diabetic nephropathy in individuals with T2DM with severe albuminuria; urine albumin/creatinine ratio (UACR) \>700 mg/g.

    Time frame: From baseline to end inclusion (3 years)

Secondary outcomes

  1. Improved clinical diagnosis

    To investigate whether clinical variables, transcriptomic, proteomic and/or metabolomic profiles as well as genetic variation can predict the presence of diabetic nephropathy in a kidney biopsy.

    Time frame: From baseline to end inclusion (3 years)

  2. diabetic retinopathy

    To describe the sensitivity and specificity of diabetic retinopathy in predicting biopsy-proven diabetic nephropathy

    Time frame: From baseline to end inclusion (3 years)

  3. Kidney Biopsy

    describe the prognostic value of different histological and molecular findings on kidney biopsy in individuals with biopsy-proven diabetic nephropathy

    Time frame: From baseline to end of followup (20 years)

  4. non-diabetic nephropathy vs. biopsy-proven diabetic nephropathy

    describe the prognostic value of different histological and molecular findings on the kidney biopsy in individuals with non-diabetic nephropathy compared to biopsy-proven diabetic nephropathy.

    Time frame: From baseline to end of followup (20 years)

  5. proteomic and metabolomic

    describe the prognostic value of the proteomic and metabolomic profiles in biopsy-proven diabetic nephropathy.

    Time frame: From baseline to end of followup (20 years)

  6. genetic variants

    describe the prognostic value of different forms of genetic variation in biopsy-proven diabetic nephropathy

    Time frame: From baseline to end of followup (20 years)

  7. Microbiome

    describe the prognostic value of different compositions of the microbiome and its relation to biopsy and clinical findings

    Time frame: From baseline to end of followup (20 years)

  8. Annual changes in kidney status

    Annual changes in kidney status (defined by yes/no: initiation of dialysis, kidney transplantation, renal death or decrease in eGFR \> 40 % compared to eGFR at baseline)

    Time frame: From baseline to end of followup (20 years)

  9. Annual decline in eGRF

    Annual decline in eGRF

    Time frame: From baseline to end of followup (20 years)

  10. Annual changes in albuminuria.

    Annual changes in albuminuria.

    Time frame: From baseline to end of followup (20 years)

  11. Annual events of cardiovascular disease

    Events of cardiovascular disease (fatal CV events, non-fatal stroke, non-fatal myocardial infarction, hospitalization for heart failure, PCI or bypass surgery (heart or legs), amputations due to ischemia, and unstable angina)

    Time frame: From baseline to end of followup (20 years)

  12. Death

    Death (any cause).

    Time frame: From baseline to end of followup (20 years)

07

Study locations

13 of 13 sites recruiting
08

References and documents

Publications

  • Moller M, Borg R, Bressendorff I, Fink LN, Gravesen E, Jensen KH, Hansen T, Krustrup D, Persson F, Rossing P, Sembach FE, Thuesen ACB, Hansen D. Rationale and design of a prospective, clinical study of kidney biopsies in people with type 2 diabetes and severely increased albuminuria (the PRIMETIME 2 study). BMJ Open. 2023 Jun 6;13(6):e072216. doi: 10.1136/bmjopen-2023-072216. PubMed 37280026 ↗

Individual participant data

Plan to share: Undecided — This topic is still up for discussion. We do plan to share most of the data, but how, time and place are still undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Dec 2043, 268 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 268 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 7, 2021
StartActual
Aug 10, 2021
Primary completionEst.
Dec 31, 2043
CompletionEst.
Dec 31, 2043
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04916132
Lead sponsor
Herlev Hospital
Collaborators
Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Responsible party
Marie Møller (MD, PhD-student, Herlev Hospital) — Principal investigator
First posted
Jun 7, 2021
Start date
Aug 10, 2021
Primary completion
Dec 31, 2043 (estimated)
Completion
Dec 31, 2043 (estimated)
Last update
Dec 24, 2025

Study contacts

Marie Møller
Contact
marie.moeller@regionh.dk
+4561695364
Ditte Hansen
Contact
ditte.hansen.04@regionh.dk
+4538682056
Frederik Persson, MD, PhD
study chair · Steno Diabetes Center Copenhagen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion